Paul Watt - Phylogica Limited Insider

Phylogica Limited -- Australia Stock  

AUD 0.04  0.00  0.00%

Chief Scientific Officer

Dr. Paul Michael Watt is NonExecutive Director of Phylogica Ltd. He is a graduate from The University of Western Australia. He completed his doctorate in Molecular Biology at Oxford University before taking up postdoctoral appointments in yeast genetics at Harvard and Oxford Universities. He discovered three novel genes, including the yeast homologue of the human Bloom and Werner syndrome genes involved in cancer susceptibility. He is an Honorary Research fellow at the Telethon Institute for Child Health Research and an Adjunct Professor at the school of Paediatrics and Child Health of the University for Western Australia. Dr. Watt has published more than 45 peer reviewed scientific papers. Dr. Watt has more than 12 years experience in commercializing intellectual property and is the primary inventor on 20 patents. He founded InfaMed Ltd., now owned by Avita Medical Ltd.
Age: 47  Executive Since 2016      
61 8 9489 7777  http://www.phylogica.com.au

Management Efficiency

The company has return on total asset (ROA) of (30.17) % which means that it has lost $30.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (26.56) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Kathryn MerweAustralia and New Zealand Banki
2017
Joanne FarrellRio Tinto Limited
2016
Arnaud SoiratRio Tinto Limited
2016
Christine ParkerWestpac Banking Corporation
2011
Harry KenyonSlaneyRio Tinto Limited
2012
Matthew ComynCommonwealth Bank of Australia
2012
Steve AllenRio Tinto Limited
2017
Tim HartinWestpac Banking Corporation
2011
Philip RichardsRio Tinto Limited
2017
Taryn MortonCommonwealth Bank of Australia
2015
Andrew CuthbertsonCSL Limited
2000
Melanie LaingCommonwealth Bank of Australia
2012
Hugo BagueRio Tinto Limited
2013
David WhiteingCommonwealth Bank of Australia
2014
Chris SalisburyRio Tinto Limited
2016
Kevin CorballyAustralia and New Zealand Banki
2016
Jason YettonWestpac Banking Corporation
2011
Vittoria ShorttCommonwealth Bank of Australia
N/A
David OvingtonRio Tinto Limited
2017
Annabel SpringCommonwealth Bank of Australia
2011
Bold BaatarRio Tinto Limited
2016

Entity Summary

Phylogica Limited offer drug discovery research and development services utilizing proprietary Phylomer peptide libraries and screening methodologies to identify peptide drug candidates for its pharmaceutical and biotechnology partners in Australia. Phylogica Limited (PYC) is traded on Australian Securities Exchange in Australia. It is located in Subiaco, WA and employs 5 people.

Did you try this?

Run Portfolio Optimization Now
   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Hide  View All  Next  Launch Portfolio Optimization
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Phylogica Limited to your portfolio

Top Management

Phylogica Limited Leadership Team
Douglas Wilson, Chairman, Ph.D
Bernard Hockings, Director, Ph.D
Paul Watt, Executive
Kevin Hart, CFO
Graeme Boden, CFO, CPA
Rudi Michelson, Executive
Rick Kendall, Director, Ph.D
Stephanie Unwin, Director
Robert Hayes, Director, Ph.D
Bruce McHarrie, Director
Natasha Forde, Executive
Richard Hopkins, CEO
Jeremy CurnockCook, Director
Rohan Hockings, Director

Stock Performance

Phylogica Limited Performance Indicators